Scientific Freedom, Responsibility and Law Program at American Association for Advancement of Science in Washington, DC, USA.
J Law Med Ethics. 2009 Winter;37(4):625-8. doi: 10.1111/j.1748-720X.2009.00435.x.
As nanotechnology emerges as an important public policy issue, the FDA's relationship with society is about to be tested. Most would agree that fostering public input will be critical to developing effective public policy for nanotechnology. Yet, it will not be easy. Low public confidence in the FDA, the general lack of knowledge about nanotechnology among ordinary Americans, and the way in which the "average" citizen obtains and evaluates knowledge about a public policy issue all pose serious challenges to any public outreach by the FDA. It will be necessary for the FDA to be attentive to not only its own public messages, but also to who is listening and how those messages are being perceived.
随着纳米技术成为一个重要的公共政策问题，食品和药物管理局（FDA）与社会的关系即将受到考验。大多数人都认为，培养公众的参与对于制定有效的纳米技术公共政策至关重要。然而，这并不容易。公众对 FDA 的信心较低，普通美国人对纳米技术的普遍了解有限，以及“普通”公民获取和评估公共政策问题知识的方式，都对 FDA 的任何公众宣传构成了严峻挑战。FDA 不仅需要关注自己的公共信息，还需要关注谁在倾听以及这些信息是如何被感知的。
